A Phase II clinical trial is under way at Northwestern Memorial Hospital in conjunction with the Northwestern University Feinberg School of Medicine to determine if bevacizumab (also referred to as Avastin®, an anti-angiogenesis drug that is designed to inhibit the growth of blood vessels in tumors) in combination with abdominal radiation therapy and chemotherapy can reduce localized pancreatic tumors that have not metastasized or spread to other systems or organs in the body. Northwestern Memorial is the sole clinical site where the research trial is being conducted.
